Concurrent with the US FDA's approval of the first therapeutic cancer vaccine, and
supported by mounting clinical evidence indicating that targeting carcinoembryonic antigen …

Carcinoembryonic antigen (CEA) is a glycosylated cell surface oncofetal protein involved in
adhesion, proliferation, and migration that is highly upregulated in multiple carcinomas and …

Carcinoembryonic antigen (CEA), a glycosylated protein of MW 180 kDa, is overexpressed
in a wide range of human carcinomas, including colorectal, gastric, pancreatic, non-small …

Advances in molecular biology and immunology have renewed interest in the development
of vaccines for the treatment or prevention of cancer. Research over the past 10 years has …

PURPOSE: To describe the features of carcinoembryonic antigen (CEA) that are important
for its use in vaccination approaches and review the clinical experience with therapeutic …

Concurrent with US Food and Drug Administration (FDA) approval of the first therapeutic
cancer vaccine, a wide spectrum of other cancer vaccine platforms that target a diverse …

Therapeutic vaccines are a promising alternative for active immunotherapy for different types
of cancers. Therapeutic cancer vaccines aim to prevent immune system responses that are …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

In recent years, there has been a surge of interest in tumor microenvironment-associated
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …

Cancer vaccines have been shown clinically to drive tumor-reactive cell activation,
proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer …